Abstract #1685. 14Anti-ICOS mAb (BMS-986226) Investigator Brochure Version 1. Bristol-Myers Squibb Company; 2017. Document Control No. Revised Protocol No.: 04 Date: 31-May-2019 154 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 15Nonclinical evaluation of the pharmacokine tics and pharmacodynamics of BMS-986226 (Study NCPK302). Bristol-Myers Squibb Company; 2017.